• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Worldwide Prescription Drug Market for Women's Health Forecast to Grow to $11.6 Billion in 2009

Posted on: Friday, 5 August 2005, 12:12 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c21987) has announced the addition of Worldwide Prescription Drug Market for Women's Health: Now and Future 2004-2009 to their offering

This report looks at the worldwide prescription drug market for women's health and estimates the market outlook to 2009. The research study shows that, while the global economy has had its ups and downs, this report projects that the market will grow to about $116 billion in 2009 and will grow at a rate of about 16.6% (CAGR).

Substantial unmet need exists in the women's health field and this report identifies the profitable marketing opportunities pharmaceutical companies can pursue by developing their businesses to include this market. In this report, diseases and conditions that particularly affect women at a rate of 55% or greater of the population of the industrialized world have been identified. As a result, women have some unique health needs. The women's broad range of healthcare needs makes them a more lucrative marketing target than men.

Readers receive detailed data and analysis about important worldwide pharmaceutical industry developments. The research report discusses the main therapeutic areas of women(1)s diseases or conditions with a brief description of the disease; patient populations, incidence, prevalence and mortality; gives the drug market size by disease; market participants; current drug treatments and revenues; market trends; new Rx drug R&D pipeline and its potential year to launch.

Pharmaceutical and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous women's health pharmaceutical industry topics with interesting and useful findings. Over 37 tables and 15 figures illustrate the findings throughout this 'must have' study.

Detailed information about the business and R&D activities of the top pharmaceutical and biotechnology companies is listed in many areas of this report - including more than 29 company profiles. Each profile includes financial data, current Rx drugs, "female adjusted" revenue estimates by indication, late stage drugs in the pipeline and likely launch year.

Companies Profiled:

-- Abbott Labs

-- Akzo Nobel

-- Allergan

-- Amgen

-- Astellas Pharma

-- AstraZeneca

-- Barr Labs

-- Bayer Healthcare

-- Biogen-Idec

-- Bristol-Myers Squibb

-- Chiron

-- Eli Lilly

-- Forest Laboratories

-- Genentech

-- Gilead Sciences

-- GlaxoSmithKline

-- Johnson & Johnson

-- Kyowa Hakko

-- Merck & Co

-- Novartis AG

-- Pfizer

-- Roche Group

-- Sanofi-Aventis

-- Schering AG

-- Schering-Plough

-- Serono AG

-- Shire Pharmaceutical

-- Solvay Pharmaceuticals

-- Takeda Chemical

-- Teva Pharmaceuticals

-- Warner Chilcott PLC

-- Watson Pharmaceuticals

-- Wyeth Pharmaceuticals

For more information visit http://www.researchandmarkets.com/reports/c21987

Source: Business Wire

More News in this Category